Blueprint Medicines Corp (NASDAQ:BPMC)’s traded shares stood at 0.58 million during the latest session, with the company’s beta value hitting 0.83. At the last check today, the stock’s price was $98.66, to imply an increase of 10.24% or $9.16 in intraday trading. The BPMC share’s 52-week high remains $121.90, putting it -23.56% down since that peak but still an impressive 25.97% since price per share fell to its 52-week low of $73.04. The company has a valuation of $6.37B, with an average of 0.79 million shares in intraday trading volume over the past 10 days and average of 1.06 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Blueprint Medicines Corp (BPMC), translating to a mean rating of 1.65. Of 10 analyst(s) looking at the stock, 0 analyst(s) give BPMC a Sell rating. 0 of those analysts rate the stock as Overweight while 4 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.51.
Blueprint Medicines Corp (NASDAQ:BPMC) trade information
After registering a 10.24% upside in the latest session, Blueprint Medicines Corp (BPMC) has traded red over the past five days. The 5-day price performance for the stock is 14.60%, and 14.80% over 30 days. With these gigs, the year-to-date price performance is 13.12%. Short interest in Blueprint Medicines Corp (NASDAQ:BPMC) saw shorts transact 5.56 million shares and set a 4.67 days time to cover.
The extremes give us $150 and $150 for target low and target high price respectively. As such, BPMC has been trading -52.04% off suggested target high and -52.04% from its likely low.
Blueprint Medicines Corp (BPMC) estimates and forecasts
The rating firms project that company’s revenue will grow 42.88% compared to the previous financial year.
Revenue forecast for the current quarter as set by 17 analysts is 171.63M. Meanwhile, for the current quarter, a total of 17 analyst(s) estimate revenue growth to 190.11M.Earnings reports from the last fiscal year show that sales brought in 138.16M and 128.18M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 24.23% before jumping 48.31% in the following quarter.
BPMC Dividends
Blueprint Medicines Corp has its next earnings report out on 2025-Feb-12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Blueprint Medicines Corp (NASDAQ:BPMC)’s Major holders
Blueprint Medicines Corp insiders hold 0.87% of total outstanding shares, with institutional holders owning 106.18% of the shares at 107.11% float percentage. In total, 106.18% institutions holds shares in the company, led by BLACKROCK INC.. As of 2024-06-30, the company held over 6.65 million shares (or 10.5758% of shares), all amounting to roughly $716.45 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 6.54 million shares, or about 10.4026% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $704.72 million.
We also have T. Rowe Price New Horizons Fund, Inc. and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Blueprint Medicines Corp (BPMC) shares. Going by data provided on Dec 31, 2024 , T. Rowe Price New Horizons Fund, Inc. holds roughly 2.05 shares. This is just over 3.21% of the total shares, with a market valuation of $202.98 million. Data from the same date shows that the other fund manager holds a little less at 1.98, or 3.10% of the shares, all valued at about 196.29 million.
